Revolution Medicines, Inc. Board of Directors

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Dr. Mark A. Goldsmith Ph.D.

Dr. Mark A. Goldsmith Ph.D.

CEO, President & Chairman

Ms. Margaret A. Horn J.D.

Ms. Margaret A. Horn J.D.

Chief Operating Officer

Mr. Walter Reiher Ph.D.

Mr. Walter Reiher Ph.D.

Chief Information Officer

Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.

Dr. Stephen M. Kelsey FRC Path., FRCP, M.D.

President of Research & Development

Dr. Kevan M. Shokat Ph.D.

Dr. Kevan M. Shokat Ph.D.

Academic Co-Founder & Member of Scientific Advisory Board

Ms. Jan Smith Ph.D.

Ms. Jan Smith Ph.D.

Chief Scientific Officer

Dr. Martin D. Burke M.D., Ph.D.

Dr. Martin D. Burke M.D., Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Ms. Xiaolin Wang

Ms. Xiaolin Wang

Executive Vice President of Development

Mr. Jack Anders

Mr. Jack Anders

Chief Financial Officer

Dr. Michael A. Fischbach Ph.D.

Dr. Michael A. Fischbach Ph.D.

Academic Co-Founder & Member of Scientific Advisory Board

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.